To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo
works in treating patients with stage IB-IIIA non-small cell lung cancer that has been
completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.

This research trial studies genetic testing in screening patients with stage IB-IIIA
non-small cell lung cancer that has been or will be removed by surgery. Studying the genes
in a patient's tumor cells may help doctors select the best treatment for patients that have
certain genetic changes.

This screening and multi-sub-study randomized phase II/III trial will establish a method for
genomic screening of similar large cancer populations followed by assigning and accruing
simultaneously to a multi-sub-study "Master Protocol". The type of cancer trait (biomarker)
will determine to which sub-study, within this protocol, a participant will be assigned to
compare new targeted cancer therapy, designed to block the growth and spread of cancer, or
combinations to standard of care therapy with the ultimate goal of being able to approve new
targeted therapies in this setting. In addition, the protocol includes a "non-match"
sub-study which will include all screened patients not eligible for any of the
biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of
care also with the goal of approval.